IP Library Granted Patent US 7,115,374
Granted Patent B2
US 7,115,374 · App. 10/688,489 · Granted Oct 3, 2006

Compositions and methods for detecting West Nile virus

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,115,374
App. No.
10/688,489
Granted
Oct 3, 2006
Kind
B2
Abstract

Compositions, methods and kits for detecting flavivirus nucleic acids. Particularly described are oligonucleotides that are useful as hybridization probes and amplification primers for detecting very low levels of West Nile virus nucleic acids.

Claims (10)

1. A kit for amplifying a target nucleic acid sequence that may be present in a biological sample, comprising:

a first primer that consists of a 3′ terminal target-complementary sequence and optionally a first primer upstream sequence that is not complementary to said target nucleic acid sequence that is to be amplified, said 3′ terminal target-complementary sequence of said first primer consisting of 22–24 contiguous bases contained within SEQ ID NO:74, and said 3′ terminal target-complementary sequence of said first primer being fully contained within the sequence of SEQ ID NO:74, allowing for the presence of RNA and DNA equivalents; and

a second primer that consists of a 3′ terminal target-complementary sequence and optionally a second primer upstream sequence that is not complementary to said target nucleic acid sequence that is to be amplifed, said 3′ terminal target-complementary sequence of said second primer consisting of 18–31 contiguous bases contained within SEQ ID NO:59, and said 3′ terminal target-complementary sequence of said second primer being fully contained within the sequence of SEQ ID NO:59, allowing for the presence of RNA and DNA equivalents.

2. The kit of claim 1 , wherein said first primer and said second primer are each up to 60 bases in length.

3. The kit of claim 1 , wherein said 3′ terminal target-complementary sequence of said second primer is up to 22 bases in length.

4. The kit of claim 3 , wherein said first primer comprises said first primer upstream sequence.

5. The kit of claim 4 , wherein said first primer upstream sequence comprises a promoter sequence for T7 RNA polymerase.

6. The kit of claim 3 , wherein said 3′ terminal target-complementary sequence of said first primer is selected from the group consisting of SEQ ID NO:75, SEQ ID NO:76 and SEQ ID NO:77, and wherein said 3′ terminal target-complementary sequence of said second primer is selected from the group consisting of SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70 and SEQ ID NO:71.

7. The kit of claim 1 , wherein said first primer comprises said first primer upstream sequence.

8. The kit of claim 7 , wherein said first primer upstream sequence comprises a promoter sequence for T7 RNA polymerase.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 028810 FRAME: 0745. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY AGREEMENT. Recorded Nov 9, 2017
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 044432/0565 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 8081301 PREVIOUSLY RECORDED AT REEL: 035820 FRAME: 0239. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST RELEASE. Recorded Nov 9, 2017
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 044727/0529 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE REEL/FRAME 028810/0745 Recorded Jun 4, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 035820/0239 →
SECURITY AGREEMENT Recorded Aug 1, 2012
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 028810/0745 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2004
From: LINNEN, JEFFREY M.; POLLNER, REINHOLD B.; WU, WEN; DENNIS, GEOFFREY G.; DARBY, PAUL M.
To: GEN-PROBE, INCORPORATED
Reel/Frame 014264/0586 →